PRESS RELEASE published on 07/29/2025 at 07:00, 9 months 19 days ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 10 months 27 days ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
BRIEF published on 06/20/2025 at 07:05, 10 months 27 days ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
PRESS RELEASE published on 06/20/2025 at 07:00, 10 months 27 days ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 11 months 5 days ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
BRIEF published on 06/12/2025 at 11:05, 11 months 5 days ago Relief Therapeutics annonce les résultats de son assemblée générale annuelle États Financiers Réunion Annuelle Approbation Des Actionnaires Élections Du Conseil D'administration Approbation De L'indemnisation
PRESS RELEASE published on 06/12/2025 at 11:00, 11 months 5 days ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 11 months 26 days ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
BRIEF published on 05/22/2025 at 07:05, 11 months 26 days ago Relief Therapeutics obtient la désignation de maladie pédiatrique rare de la FDA pour le RLF-TD011 FDA THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Maladie Pédiatrique Rare
PRESS RELEASE published on 05/22/2025 at 07:00, 11 months 26 days ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
Published on 05/16/2026 at 01:15, 1 day 21 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 1 day 22 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 23 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/16/2026 at 16:08, 1 day 6 hours ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 2 days 2 hours ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 2 days 4 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 2 days 7 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 7 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 12 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 13 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 4 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
